Oral Treatment for Gonorrhea
There is no longer a recommended first-line oral-only treatment for gonorrhea—intramuscular ceftriaxone 250-500 mg plus oral azithromycin 1 g is the current standard of care. 1, 2
Current Treatment Paradigm
The CDC explicitly discontinued oral cefixime as a first-line regimen in 2012 due to rising minimum inhibitory concentrations (MICs) and concerns about accelerating cephalosporin resistance 1. This represents a critical shift from earlier guidelines that included oral options.
Primary Recommended Regimen
- Ceftriaxone 500 mg IM single dose (updated from 250 mg in 2020) 2
- PLUS Azithromycin 1 g orally single dose (preferred over doxycycline due to better compliance and lower gonococcal tetracycline resistance) 1
The dual therapy approach serves two purposes: treating possible chlamydial coinfection and theoretically delaying cephalosporin resistance through different mechanisms of action 1.
When Oral-Only Treatment May Be Considered
Alternative Regimen (Only if Ceftriaxone Unavailable)
If injectable ceftriaxone cannot be administered:
- Cefixime 400 mg orally single dose
- PLUS Azithromycin 1 g orally single dose
- PLUS mandatory test-of-cure in 1 week 1
Critical caveat: Cefixime provides lower and less sustained bactericidal levels than ceftriaxone and has limited efficacy for pharyngeal gonorrhea (only 78-89% cure rate) 1, 3. A meta-analysis found cefixime cured 97% of urogenital infections but only 89% of pharyngeal infections 3.
Severe Cephalosporin Allergy
- Azithromycin 2 g orally single dose
- PLUS mandatory test-of-cure in 1 week 1
This is a last-resort option with concerns about rapid resistance emergence 4.
Why Oral Options Are No Longer Preferred
The evidence shows a clear trajectory away from oral therapy:
Rising resistance patterns: Cefixime MICs increased significantly from 2006-2012, particularly in the Western US and among men who have sex with men—the same pattern that preceded fluoroquinolone resistance spread 1
Pharyngeal treatment failure: The pharynx is the most common site of treatment failure and serves as a reservoir for resistance development 5. Oral cefixime demonstrates poor pharyngeal efficacy compared to IM ceftriaxone 1, 3
Preservation of ceftriaxone: Continued cefixime use may hasten resistance to ceftriaxone, "the last antimicrobial that is recommended and known to be highly effective" 1
Historical Context (No Longer Applicable)
Older guidelines (2002-2006) included fluoroquinolones (ciprofloxacin 500 mg, ofloxacin 400 mg, levofloxacin 250 mg) as oral options 6, 4. These are completely obsolete due to widespread quinolone-resistant N. gonorrhoeae (QRNG) and should never be used 4.
Common Pitfalls to Avoid
- Do not use oral-only therapy for pharyngeal gonorrhea without understanding the high failure risk
- Do not skip the test-of-cure when using alternative oral regimens—this is mandatory, not optional 1
- Do not use single-agent azithromycin 1 g—this dose cures only 93% of infections and risks rapid resistance 7
- Always treat presumptively for chlamydia unless definitively ruled out, as coinfection rates are substantial 1
Treatment Failure Management
If a patient fails oral alternative therapy, immediately:
- Obtain culture with antimicrobial susceptibility testing
- Report to local health department within 24 hours
- Treat with gentamicin 240 mg IM plus azithromycin 2 g orally 5
- Consult infectious disease specialist 1, 5
The bottom line: While oral treatment for gonorrhea was once standard, antimicrobial resistance has eliminated this as a reliable first-line approach. Injectable ceftriaxone remains the cornerstone of therapy, with oral options reserved only for situations where IM administration is truly impossible—and even then, with mandatory follow-up testing.